- Home
- XFOR vs NTIC Comparison
XFOR vs NTIC Comparison
Compare XFOR & NTIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- NTIC
- Stock Information
- Founded
- XFOR 2014
- NTIC 1970
- Country
- XFOR United States
- NTIC United States
- Employees
- XFOR N/A
- NTIC N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- NTIC Industrial Specialties
- Sector
- XFOR Health Care
- NTIC Industrials
- Exchange
- XFOR Nasdaq
- NTIC Nasdaq
- Market Cap
- XFOR 84.3M
- NTIC 72.5M
- IPO Year
- XFOR N/A
- NTIC N/A
- Fundamental
- Price
- XFOR $3.80
- NTIC $7.67
- Analyst Decision
- XFOR Strong Buy
- NTIC
- Analyst Count
- XFOR 3
- NTIC 0
- Target Price
- XFOR $34.17
- NTIC N/A
- AVG Volume (30 Days)
- XFOR 1.5M
- NTIC 20.5K
- Earning Date
- XFOR 11-12-2025
- NTIC 11-18-2025
- Dividend Yield
- XFOR N/A
- NTIC 0.52%
- EPS Growth
- XFOR N/A
- NTIC N/A
- EPS
- XFOR N/A
- NTIC 0.31
- Revenue
- XFOR $32,774,000.00
- NTIC $85,268,129.00
- Revenue This Year
- XFOR $1,307.51
- NTIC $1.09
- Revenue Next Year
- XFOR N/A
- NTIC $5.69
- P/E Ratio
- XFOR N/A
- NTIC $24.59
- Revenue Growth
- XFOR 5721.31
- NTIC 3.46
- 52 Week Low
- XFOR $1.35
- NTIC $6.75
- 52 Week High
- XFOR $26.83
- NTIC $15.09
- Technical
- Relative Strength Index (RSI)
- XFOR 62.57
- NTIC 49.32
- Support Level
- XFOR $2.96
- NTIC $7.40
- Resistance Level
- XFOR $4.54
- NTIC $7.92
- Average True Range (ATR)
- XFOR 0.26
- NTIC 0.22
- MACD
- XFOR 0.08
- NTIC -0.01
- Stochastic Oscillator
- XFOR 57.47
- NTIC 32.07
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About NTIC Northern Technologies International Corporation
Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.